

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD
QUAKERBRIDGE PLAZA, BUILDING 7, Rooms 200 ABC**

October 16, 2019

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of draft meeting summary for July 17, 2019 meeting
- IV. Secretary's report
- V. Old Business
 - A. WellCare and Amerigroup breakdown of "other category" in the quarterly PA Denials Report
 - B. Horizon's absolute denials (percentage of denials not reversed) in "clinical criteria not met" category
- VI. New Business
 - A. Proposed protocol for hereditary transthyretin-mediated amyloidosis (hATTR) products
 - B. Proposed protocol Elaprase[®] (idursulfase)
 - C. Proposed protocol for Gaucher disease products
 - D. Proposed protocol for Cablivi[®] (caplacizumab-yhdp)
- VII. DURB Annual Report for SFY 2019 (July 1, 2018 thru June 30, 2019) – Board members packet
- VIII. A. Informational Highlights/Reports
 - 1. DXC Technology/NJ HMO 2nd Quarter 2019 Prior Authorization Report
 - 2. Summary of DURB Action Items
 - 3. (a) DHS, DHSS and MCO Programs Top Drugs Report (by amount paid and by category)
 - (b) Physician-administered/Antiviral drugs by amount paid
- B. Medication information:
 - (a) FDA says widening probe on generic drug impurities
 - (b) Combination benzodiazepine, antidepressant use during pregnancy warrants caution
 - (c) PPI Use in Infants With Acid Reflux Increases Early Fracture Risks
 - (d) CMS gives states, MCOs guidance on tracking Medicaid opioid use
 - (e) Study finds about 1 in 7 people with diabetes ration medicine due to cost
- IX. Referenced Materials
 - A. Approved protocol for Urea Cycle Disorder products
 - B. Approved protocol for Zolgensma (onasemnogene abeparvovec-xioi)
 - C. Approved protocol for Cuprimine[®] (penicillamine) and Syprine[®] (trientine) Used in the Treatment of Wilson's Disease, Cystinuria, and Severe, Active Rheumatoid Arthritis